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Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is a challenging clinical problem because it is relatively
uncommon, a deﬁnitive diagnosis may be difﬁcult in some
patients, and the consequence of missing the diagnosis
could be fatal. Moreover, the onset of symptoms occurs over
a broad range of age. Worldwide registries and consensus
documents have improved the criteria used to make the
diagnosis and serve to disseminate information to physicians
who do not see patients with this problem very often. The
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medical and family history, electrocardiographic (ECG)
characteristics, and morphological criteria on the basis of
cardiac catheterization, echocardiography, cardiac magnetic
resonance (CMR), or myocardial biopsy are synthesized
to make the diagnosis on the basis of the proposed 2010 task
force criteria (1). The proposed guidelines for CMR criteria
require the combination of severe regional wall motion
abnormalities with global right ventricular dilation or
dysfunction. Although these criteria maintain speciﬁcity,
they may not have improved sensitivity for diagnosis (2).
Moreover, interpretation of the results of diagnostic studies
such as CMR is dependent on experience, and results from
the North American Multidisciplinary Study have shown
signiﬁcant differences in the interpretation of diagnostic test
results at referral centers compared with core laboratories (3).
The rate of progression of the disease has not been delin-
eated, and with the advent of genetic testing, physicians are
likely to be consulted about the management of asymptomatic*Editorials published in the Journal of the American College of Cardiology reﬂect the
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to disclose.carriers of desmosomal protein mutations, which is difﬁcult
to assess because of variable disease expression even within
the same family (4). There is some evidence that electro-
physiological abnormalities precede histological changes, as
reported by Gomes et al. (5) in a murine model with condi-
tional genetic deletion of 1 allele of desmoplakin and ﬁndings
in patients carrying desmoplakin mutations. With progres-
sion of disease, adverse outcomes may be associated with
more than 1 mutation or the development of biventricular
dysfunction (4,6).
The diagnostic role of electrophysiologic studies is limited.
Endocardial voltage mapping may be misleading because
much of the scar and substrate for arrhythmias are epicardial
(7). It seems unlikely that electrophysiologic studies would
improve risk stratiﬁcation in patients who appear to be
evolving the substrate for sustained ventricular arrhythmias.
Although abnormalities on signal-averaged electrocardiog-
raphy are common in patients with ARVC and may support
the diagnosis, they have not predicted adverse events with
high speciﬁcity (8).
Uncertainty about the diagnosis, rate of progression of
disease, and risk for sudden death could result in unnecessary
procedures or recommendations to implant implantable
cardioverter-deﬁbrillators in the absence of any clear data to
support the decision. In this issue of the Journal, te Riele et al.
(9) report their evaluation of the incremental value of ECG
and Holter abnormalities and CMR to assess the risk for
sustained ventricular tachycardia or ventricular ﬁbrillation in
69 patients with ARVC. The patients all had documented
mutations but had never had sustained ventricular arrhyth-
mias at entry to the study. Over a mean follow-up period of
5.8  4.4 years, only 1 patient with normal ECG and Holter
ﬁndings had abnormal CMR results. Among those with
electrical abnormalities, deﬁned as abnormal Holter results
(frequent premature ventricular complexes or nonsustained
ventricular tachycardia) or ECG characteristics of ARVC,
approximately half had abnormal results on CMR. During
follow-up, 16% of patients developed sustained ventricular
arrhythmias, and these occurred only in patients with elec-
trical abnormalities who also had abnormal CMR results.
These data suggest that electrical abnormalities appear to
precede abnormalities onCMR and that the risk for sustained
ventricular arrhythmias is relatively high in patients with both
electrical abnormalities and abnormal CMR ﬁndings, but the
risk is low if these ﬁndings are normal or only 1 study shows
abnormal results. The number of patients studied is modest,
but the data are very intriguing.
te Riele et al. (9) have made a valuable contribution to our
understanding of ARVC, but the study had several limita-
tions. The baseline studies used to establish electrical and
CMR abnormalities were performed when the patients were
enrolled, but we do not know whether these abnormalities
progressed over time, because the tests were not repeated at
scheduled intervals or at the conclusion of the study. More-
over, although a mean follow-up period exceeding 5 years is
acceptable for most conditions, it is a small segment of time in
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1771a patient who is diagnosed at a relatively young age and carries
a genetic abnormality for life. What does the absence of
electrical or CMR abnormalities mean for a subject 25 years
of age who has a mutation associated with ARVC and is
contemplating a family or career? It may be reassuring in the
short term, but we need to establish appropriate guidelines for
follow-up without creating undue anxiety.
One of the challenges of developing clear practice
guidelines for a relatively uncommon problem with variable
genetic penetrance and a low incidence of potentially fatal
arrhythmias is that a large trial is required to prove the
predictive value of diagnostic tests or the long-term beneﬁts
of interventions. Moreover, the costs of obtaining lifetime
follow-up data and the infrastructure required to monitor it
are formidable. The results reported by te Riele et al. (9)
raise several questions that require a long-term, large-scale
study. Their data suggest that electrical abnormalities
precede the development of anatomic abnormalities. What
is the interval of time before patients with electrical
abnormalities develop anatomic changes detectable by
CMR? Can we state categorically that carriers of desmo-
somal protein mutations do not require CMR until they
have evidence of electrical abnormalities? Should asymp-
tomatic carriers with both electrical and anatomic abnor-
malities be advised to undergo placement of an implantable
cardioverter-deﬁbrillator? Are the results of this study
applicable to the broader population, or is there an unin-
tended bias when a major referral center performs a study of
this nature? A conservative approach is warranted for
asymptomatic carriers who are not enrolled in studies
designed to answer these difﬁcult questions. It would be
premature to alter guidelines on the basis of this study, but
it would be appropriate for physicians to provide closer
follow-up in patients with combined electrical and CMR
abnormalities.Reprint requests and correspondence: Dr. Bruce D. Lindsay,
Cleveland Clinic, Department of Cardiology, 9500 Euclid Avenue,
J2-2, Cleveland, Ohio 44195. E-mail: lindsab@ccf.org.REFERENCES
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